Both medicines have heart-rhythm precautions. Fainting with palpitations, a seizure, collapse, or fever with confusion and marked stiffness requires urgent assessment. Do not combine the medicines or substitute equal milligram amounts.
Escitalopram and citalopram have similar names because they are closely related medicines. They are nevertheless different prescriptions, with different strengths, product instructions and licensed indications. Both belong to the SSRI antidepressant class. The similarity can create confusion when a prescription changes, particularly if tablets look different or a familiar brand is unavailable. Understanding the relationship helps prevent errors, but does not provide a reason to switch without a clinical plan.
What is the chemical relationship?
Citalopram contains two mirror-image molecular forms, called enantiomers. Escitalopram contains the S form. This is a pharmacological distinction, not evidence that citalopram contains an unnecessary filler or that escitalopram is automatically a superior treatment. The effect of a medicine still needs to be judged in the individual person. [1]
Both influence serotonin reuptake. The mechanism does not establish that someone’s depression or anxiety is caused by a simple measurable serotonin shortage. Treatment decisions instead draw on clinical evidence, diagnosis, previous experience, safety and the person’s priorities. A molecular explanation is useful background, not a personalized prescribing algorithm.
Names, brands and avoiding mix-ups
Escitalopram may be familiar as Lexapro or Cipralex, while citalopram may be called Celexa or Cipramil. Brand availability differs by country and changes over time. Check the generic name on each box. The escitalopram and citalopram guides provide separate reference information.
When a prescription changes, ask the pharmacist to explain which supply to use and what should happen to the old one. Do not take both because the names appear related. Keep the written plan and the current medicine list together, particularly during travel or when more than one clinician is involved. Uncertainty about a label should be resolved before taking an extra tablet.
Depression and anxiety applications
Both medicines are used for depression. Escitalopram also has roles in several anxiety-related conditions, while citalopram has depression and panic-disorder uses in UK patient guidance. Exact indications vary by country and product. One medicine’s approval should not be assumed to apply to the other, or to every age group. [2] [3]
An off-label prescription is not necessarily inappropriate, but the reason and evidence should be clear. Ask whether the target is depression, persistent generalized anxiety, panic, obsessive-compulsive symptoms or another condition. The distinction affects how progress is measured, how psychological therapy fits the plan and how long an adequate treatment assessment may take.
Is one more effective?
This comparison does not identify a universal winner. Individual response, tolerability and previous treatment can outweigh a general impression about a medicine. Someone who has benefited from citalopram should not assume that a related medicine will improve the result simply because it is described as newer or more selective.
A useful review asks what remains unresolved. Is the medicine ineffective, partly effective, difficult to tolerate or hard to take consistently? Those are different problems. The clinician may recommend continuing, adjusting the broader plan, changing medication or reassessing the diagnosis. The decision should be linked to a specific goal rather than a marketing-style ranking.
Dose numbers are not directly interchangeable
The same numerical dose does not represent the same prescription across these medicines. Differences in composition, product labeling and exposure mean that a switch needs actual instructions. This guide intentionally gives no dose equivalence. Taking a matching number from a different box can produce an unintended change in treatment.
Liquid products add another layer of complexity. Concentration, drop size and bioavailability can vary, so a tablet-to-liquid change is not simply a matter of matching volume. Use the supplied measuring device and ask the pharmacist to verify the product-specific instructions. Never use a household spoon or another medicine’s drop count as a substitute.
QT interval and heart-rhythm precautions
Both citalopram and escitalopram can prolong the QT interval in a dose-dependent manner. Relevant risk factors include certain heart conditions, slow heart rate, low potassium or magnesium and other medicines that prolong QT. The MHRA describes restrictions and monitoring considerations for both drugs; escitalopram should not be described as having no cardiac risk. [1]
Heart history can therefore change a treatment decision. Depending on the circumstances, a clinician may consider an electrocardiogram, electrolyte testing or another antidepressant. NHS Specialist Pharmacy Service lists both medicines as less preferred choices in coronary heart disease. This is a reason for individualized review, not an instruction to discontinue a stable prescription independently. [4]
Side effects and daily functioning
Digestive symptoms, headaches, sweating, altered sleep and sexual problems can occur with either medicine. Feeling more anxious or restless early in treatment also deserves discussion, especially when pronounced or persistent. A side effect that disrupts eating, work, relationships or adherence is clinically relevant even when it is not an emergency. [2] [3]
Describe what changed rather than deciding the cause in advance. Record the date, actual use, other medicines and the effect on daily activities. Ask what can reasonably be monitored and what requires an earlier appointment. Do not drive or operate dangerous equipment while dizzy, drowsy or otherwise impaired.
Sexual symptoms and persistent concerns
Sexual function can be affected by depression, anxiety, other illnesses and antidepressant treatment. Explain whether changes began before or after the medicine and which aspect is troublesome. Product information also acknowledges reports of sexual symptoms persisting after stopping an SSRI; persistent difficulties deserve assessment rather than dismissal. [5]
There is no guarantee that changing between these two medicines will resolve a particular problem. A review should consider the whole picture, including other prescriptions and relationship or physical-health factors. The sexual side-effects guide can help prepare the conversation without experimenting with missed doses.
Interactions and medical history
Other serotonergic medicines, MAO inhibitors, certain painkillers and supplements can create important interactions. Medicines that affect bleeding or heart rhythm also need review. Some treatments, including certain acid-suppressing medicines, can increase citalopram or escitalopram exposure. A full pharmacy check is more useful than checking only the main psychiatric prescription. [1]
Tell the clinician about liver disease, seizures, previous mania or hypomania, pregnancy plans and breastfeeding. Age and physical health can affect prescribing limits and monitoring. Bring medicines purchased abroad, non-prescription remedies and supplements to the discussion. An incomplete list can hide a risk that is unrelated to the antidepressant’s brand.
Serious symptoms need prompt assessment
New suicidal thoughts, a major increase in agitation or unusually elevated mood needs prompt clinical contact. Immediate suicidal danger, a seizure, collapse, severe allergy or fever with confusion and marked muscle stiffness requires urgent help. Fainting with palpitations is particularly important when discussing QT-related risk. [6]
Do not wait for a routine review or an admissions response when urgent symptoms are present. Tell the emergency team about both current and recently stopped medicines. A serious reaction and routine treatment adjustment are different situations; a general instruction about gradual withdrawal must not delay emergency assessment.
Withdrawal and planned switching
Both medicines can cause withdrawal symptoms after a reduction or interruption. This is distinct from the pattern of addiction associated with seeking intoxication, but it can still be difficult and disruptive. New dizziness, sensory symptoms, anxiety or sleep disturbance after a change should be assessed alongside possible recurrence of the original condition.
A clinician-led switch should explain what to take, what to stop, the review arrangement and how to obtain help. The method depends on the actual regimen and history. Do not overlap leftover supplies or invent a reduction schedule. The withdrawal-or-relapse guide explains why symptom timing informs an assessment without proving the diagnosis.
Mental health alongside addiction treatment
Neither medicine is a stand-alone treatment for acute alcohol, opioid or sedative withdrawal. They may be relevant to a co-occurring depressive or anxiety disorder, but that assessment should consider substance exposure and the timing of symptoms. Treatment services should coordinate rather than make isolated changes to one part of a complex regimen.
Agree who is responsible for the antidepressant during residential care, hospital treatment or a move between countries. Maintaining accurate information about the active ingredient is particularly important with these similar names. A continuing-care plan should prevent accidental duplication and unplanned interruption.
Preventing confusion during a prescription change
Because the names are so similar, ask for the agreed medicine to be written out in full. Check that the pharmacy label matches the clinician’s instructions and that an old repeat prescription has not created an unintended duplicate supply. A photograph of the current packaging can help during an appointment, but it should not replace the written plan when the product or formulation changes.
Explain any practical obstacles before leaving the consultation. These might include difficulty swallowing tablets, trouble measuring a liquid, irregular work hours or reliance on a carer to organize medicines. The appropriate response is to make the regimen understandable and feasible, not to improvise by breaking tablets or alternating between products. A pharmacist can help clarify the actual preparation and measuring device supplied.
During follow-up, review the question that prompted the change rather than simply asking whether the new name feels better. Record the original symptom, any adverse effects and the impact on daily life. Make sure the clinician knows about recently stopped treatment and other prescriptions. Clear documentation is especially valuable when a person travels, changes primary-care practice or enters another treatment setting. It allows the receiving team to verify the intended regimen instead of guessing from an incomplete medicine list.
Frequently asked questions
Are escitalopram and citalopram the same drug?
No. They are closely related, but have distinct products and prescribing instructions. Their names should never be treated as spelling variants of one prescription.
Is escitalopram free of citalopram’s heart risks?
No. Both have QT-related precautions. The person’s cardiac history, other medicines, exposure and monitoring needs matter more than a simple safer-versus-unsafe label.
What should determine a switch?
A clear clinical reason, an agreed goal and a practical plan. Bring the current packaging and a record of benefit and adverse effects to the medication review.
Evidence and sources
- [1] MHRA: Citalopram and escitalopram, QT interval prolongation.
- [2] NHS: Escitalopram.
- [3] NHS: Citalopram.
- [4] NHS Specialist Pharmacy Service: Antidepressants in coronary heart disease.
- [5] AEMPS CIMA: Citalopram Normon product information.
- [6] DailyMed: Citalopram prescribing information.
